AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Conditions: Follicular Lymphoma; Mantle Cell Lymphoma; Hairy Cell Leukemia; Lymphoplasmacytic Lymphoma; Burkitt Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia Interventions: Drug: CD22CART Infusion Sponsors: Stanford University; The Leukemia and Lymphoma Society Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials